First patient dosed in Adverum wet AMD gene therapy trial

The first patient has been dosed in a phase 1 trial of ADVM-022 gene therapy for wet age-related macular degeneration, Adverum Biotechnologies announced in a release.

The multicenter, open-label OPTIC phase 1 trial is designed to assess the safety and tolerability of a single intravitreal administration of ADVM-022. Eighteen patients will be enrolled in the trial, which will evaluate three doses of the therapy: 6 × 10^11 vg/eye, 2 × 10^12 vg/eye and 6 × 10^12 vg/eye, the release said.

“This milestone is the next step in bringing a new meaningful option to patients that may provide long-lasting therapy without the need of chronic or frequent anti-VEGF injections,” Adverum CEO Leone Patterson said in the release. “We look forward to providing an interim update of this phase 1 by the first quarter of 2020.”

The first patient has been dosed in a phase 1 trial of ADVM-022 gene therapy for wet age-related macular degeneration, Adverum Biotechnologies announced in a release.

The multicenter, open-label OPTIC phase 1 trial is designed to assess the safety and tolerability of a single intravitreal administration of ADVM-022. Eighteen patients will be enrolled in the trial, which will evaluate three doses of the therapy: 6 × 10^11 vg/eye, 2 × 10^12 vg/eye and 6 × 10^12 vg/eye, the release said.

“This milestone is the next step in bringing a new meaningful option to patients that may provide long-lasting therapy without the need of chronic or frequent anti-VEGF injections,” Adverum CEO Leone Patterson said in the release. “We look forward to providing an interim update of this phase 1 by the first quarter of 2020.”